Schneider Children's Medical CenterIsrael
Anti-TNF Drug(Schneider Children's Medical Center, Israel)은 Crohn Disease 표적 치료제로, Crohn Disease 영역에서 개발·상용화 중입니다. 작용기전: targeted disruption of the physiological pathway. 전임상 단계입니다. 대표 임상 효능: ORR 1.8% (ClinicalTrials.gov NCT00124982). PK: t½ 248.54 days. 차별점: novel immunology antibody-drug conjugate, ABBV-3373, in healthy participants.
Crohn Disease
Crohn Disease
Recruiting
bispecific antibodies
has
linkers (GGGGS)
humanized mouse Imiquimod-induced psoriasis and 2,4,6‑trinitrobenzene sulfonic acid colitis models, an
novel immunology antibody-drug conjugate, ABBV-3373, in healthy participants
targeted disruption of the physiological pathway
immune-mediated inflammatory diseases
payload), has the potential to treat immune-mediated inflammatory diseases
biomarkers, and integrating and disseminating effective interventions into community and clinical practice to
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Schneider Children's Medical CenterIsrael
Anti-TNF Drug(Schneider Children's Medical Center, Israel)은 Crohn Disease 표적 치료제로, Crohn Disease 영역에서 개발·상용화 중입니다. 작용기전: targeted disruption of the physiological pathway. 전임상 단계입니다. 대표 임상 효능: ORR 1.8% (ClinicalTrials.gov NCT00124982). PK: t½ 248.54 days. 차별점: novel immunology antibody-drug conjugate, ABBV-3373, in healthy participants.
Crohn Disease
Crohn Disease
Recruiting
bispecific antibodies
has
linkers (GGGGS)
humanized mouse Imiquimod-induced psoriasis and 2,4,6‑trinitrobenzene sulfonic acid colitis models, an
novel immunology antibody-drug conjugate, ABBV-3373, in healthy participants
targeted disruption of the physiological pathway
immune-mediated inflammatory diseases
payload), has the potential to treat immune-mediated inflammatory diseases
biomarkers, and integrating and disseminating effective interventions into community and clinical practice to
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.